ZEVRA THERAPEUTICS, INC. 8-K

What Happened
Zevra Therapeutics, Inc. filed an 8-K on March 9, 2026 announcing it issued a press release with its financial results and corporate updates for the quarter and year ended December 31, 2025, and scheduled a conference call/webcast for March 9, 2026 at 4:30 p.m. ET. Separately, the company announced the appointment of Justin Renz as Chief Financial Officer and Treasurer effective March 9, 2026, and as principal financial officer effective March 10, 2026; Timothy Sangiovanni will cease serving as principal financial officer as of March 10, 2026.

Key Details

• Press release announcing Q4 and year-end 2025 results furnished as Exhibit 99.1 (dated March 9, 2026); conference call/webcast scheduled March 9, 2026 at 4:30 p.m. ET.
• Justin Renz (age 54) appointed CFO/Treasurer (effective March 9) and principal financial officer (effective March 10); press release dated March 5, 2026 furnished as Exhibit 99.2.
• Employment terms: $520,000 annualized base salary and annual performance bonus target of 45% of base salary.
• Equity: option to purchase 300,000 shares under the company’s inducement award plan; option vests over four years (25% each year).
• Severance: if terminated without cause or resigns for good reason, 12 months continued base salary, prorated annual target bonus for year of termination, and acceleration of vesting for awards that would have vested during the 12-month severance period (subject to release and restrictive covenants).

Why It Matters
For investors, the filing signals two material items: (1) the company has released its Q4/2025 financial results and held (or will hold) a public briefing, which may affect near-term stock reaction depending on the reported results, and (2) a leadership change at the finance function with an experienced biopharma CFO joining the company under standard compensation and severance terms. The CFO change affects who signs off on financial reporting and investor communications; the compensation and equity terms reveal the company’s incentives and potential future share dilution.